This study is testing a new treatment called C5252 for people with glioblastoma, a type of brain tumor, that has come back or gotten worse after previous treatments. C5252 is given as a single injection directly into the tumor. The main goals of this Phase 1 study are to find out if C5252 is safe, what side effects it might cause, and to determine the highest dose that can be given safely. The study plans to enroll about 51 participants. Currently, the study's recruitment status is unclear.

Study design

This is a Phase 1, open-label study, meaning both you and your doctors will know which treatment you are receiving. It will enroll approximately 51 participants to evaluate escalating doses of C5252.

What's involved

You would receive a single injection of C5252 directly into your tumor on Day 1. The study will then monitor your safety and tolerability for up to 28 days after the injection.

Compensation

Not stated in the trial record.

Follow-up

Your safety and tolerability will be evaluated for up to 28 days from the C5252 injection.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.